The SYT11 antibody targets Synaptotagmin 11 (SYT11), a member of the synaptotagmin family, which are calcium-binding proteins implicated in membrane trafficking and synaptic vesicle regulation. Unlike other synaptotagmins linked to neurotransmitter release, SYT11 lacks canonical calcium-binding motifs, suggesting distinct functional roles. It is broadly expressed in neuronal and non-neuronal tissues, including the brain, pancreas, and adrenal glands, and is associated with intracellular trafficking, autophagy, and lysosomal function. SYT11 has garnered attention in neurodegenerative research, particularly Parkinson’s disease (PD), as it interacts with alpha-synuclein, a key protein in PD pathology. Studies link SYT11 gene variants to PD susceptibility, and its dysregulation may contribute to impaired protein degradation pathways. Additionally, SYT11 is involved in insulin secretion in pancreatic β-cells, highlighting its metabolic relevance. Antibodies against SYT11 are crucial tools for detecting its expression and localization via techniques like Western blot, immunohistochemistry, and immunofluorescence. These studies help elucidate SYT11’s role in cellular processes and disease mechanisms, though its precise molecular functions remain under investigation. Research continues to explore its dual roles in neurodegeneration and metabolic regulation, making SYT11 a protein of growing interest in both neurological and systemic disorders.